•
Metaanalysis: 13 trials – 7611 patients (cetuximab,
panitumumab, erlotinib y gefitinib)
•
VTE 11 trials:
–
RR 1.32 CI95% 1.07-1.63; p=0.01
•
ATE 5 estudios:
–
RR 1.34 CI95% 0.94–1.9; p=0.11
•
VTE: MoAbs RR 1.34; p=0.01 and oral TKIs RR 1.16;
p=0.65
Necitumumab e20534 2016 ASCO
EGFR monoclonal antibody (moAB)
Approved in combination with gemcitabine and
cisplatin in metastatic squamous NSCLC
Analysis of four trials of 1st-line treatment for Stage IV
NSCLC
VTE was more frequent in patients on neci+chemo vs
chemo alone
SQUIRE trial RR 1.699; CI 1.09-2.65
INSPIRE trial RR 1.58; CI 0.99-2.52
Similar data with cetuximab/panitumumab,
class effect of moAb anti-EGFR?
Other anti-HER MoAb: trastuzumab, pertuzumab and TDM1 no VTE risk
